ECG monitoring of treatment response in pulmonary arterial hypertension patients

Chest

Volumn 134, Issue 6, 2008, Pages 1250-1257

  Henkens, Ivo R ^a   Gan, C Tji Joong ^b   Van Wolferen, Serge A ^b   Hew, Miki ^a   Boonstra, Anco ^b   Twisk, Jos W R ^b   Kamp, Otto ^b   Van Der Wall, Ernst E ^a   Schalij, Martin J ^a   Vonk Noordegraaf, Anton ^b   Vliegen, Hubert W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ECG; Monitoring; Pulmonary circulation; Pulmonary hypertension

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTVOID RESIDUAL URINE VOLUME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT RESPONSE;

EID: 57349184114     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-0461     Document Type: Article

References (37)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223
2. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
3. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111
4. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903
6. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26:858-863
7. Peacock A, Naeije R, Galie N, et al. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004; 23:947-953
8. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43(suppl):48S-55S
9. Henkens IR, Mouchaers KT, Vonk-Noordegraaf A, et al. Improved ECG detection of presence and severity of right ventricular pressure load validated with cardiac magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2008; 294:H2150-H2157
10. Ahearn GS, Tapson VF, Rebeiz A, et al. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002; 122:524-527
11. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278
12. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(suppl):40S-47S
13. Chemla D, Castelain V, Herve P, et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20:1314-1331
14. Lankhaar JW, Westerhof N, Faes TJ, et al. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J 2008; 29:1688-1695
15. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):14S-34S
16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-843
17. Lehtonen J, Sutinen S, Ikaheimo M, et al. Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy. Chest 1988; 93:839-842
18. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002; 121:513-518
19. Karliner JS, Sarnquist FF, Graber DJ, et al. The electrocardiogram at extreme altitude: experience on Mt. Everest. Am Heart J 1985; 109:505-513
20. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007; 115:1132-1146
21. Pipberger HV, Goldman MJ, Littmann D, et al. Correlations of the orthogonal electrocardiogram and vectorcardiogram with consitutional variables in 518 normal men. Circulation 1967; 35:536-551
22. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76:135-141
23. Kawaguchi Y. Studies on deflection area vectors of QRS and T and ventricular gradient in right ventricular hypertrophy. Jpn Circ J 1985; 49:395-405
24. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60:1025-1030
25. MacFarlane PW, Lawrie TDV. Comprehensive electrocardiology. 1st ed. Oxford, UK: Pergamon Press, 1989; 1441-1526
26. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48:2546-2552
27. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492
28. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006; 28:1190-1194
29. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108:844-848
30. Mahapatra S, Nishimura RA, Sorajja P, et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006; 47:799-803
31. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28:1250-1257
32. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123
33. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049-2056
34. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
35. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-804
36. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 2006; 130:1198-1202
37. Benza RL, Park MH, Keogh A, et al. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007; 26:437-446